FDA Approves Bayer's Kovaltry (Antihemophilic Factor (Recombinant)) for the Treatment of Children and Adults with Hemophilia A

WHIPPANY, N.J., March 17, 2016 /PRNewswire/ -- The U.S. Food and Drug Administration has approved Bayer's Kovaltry Antihemophilic Factor (Recombinant), an unmodified, full-length factor VIII compound for the treatment of hemophilia A in children and...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news